Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Reports Stock and Option Awards

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• On February 26, 2024, Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, reported the acquisition of 126,667 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in four equal annual installments, starting on the first day of the month following the one-year anniversary of the grant date, contingent upon continued service to the Issuer.
• Cohen also acquired options to purchase 190,000 shares of common stock at an exercise price of $17.56.
• These options vest, with 1/4 vesting on the first day of the month of the one year anniversary of the grant date, and the remaining shares vesting monthly over the remaining 36 months, contingent upon continued service to the Issuer.
• Following these transactions, Cohen directly owns 3,027,137 shares of Amylyx Pharmaceuticals common stock and options to purchase 190,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting schedules suggest a long-term commitment.

Positives

• The grant of RSUs and stock options to the Co-CEO aligns his interests with those of the shareholders.
• The vesting schedules of the RSUs and options incentivize continued service and commitment to the company.

Industry Context

This is a standard practice for publicly traded companies to compensate executives with stock and option awards to align their interests with shareholders and incentivize long-term performance.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry.
• Vesting schedules are typically structured to incentivize long-term employment and performance, often over a 3-4 year period.
• The specific amount of equity granted varies depending on the company's size, performance, and the executive's role.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, potentially leading to decisions that increase shareholder value.
• The vesting schedules incentivize the Co-CEO to remain with the company, providing stability and expertise.

Key Dates